Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study.

导出 LinkOut

翻译打印收藏纠错

作者： Giuseppe L,Banna ^[1] ; Ornella,Cantale ^[2] ; Sethupathi,Muthuramalingam ^[3] ; Judith,Cave ^[4] ; Charles,Comins ^[5] ; Alessio,Cortellini ^[6] ; Alfredo,Addeo ^[7] ; Alessio,Signori ^[8] ; Hayley,McKenzie ^[4] ; Carles,Escriu ^[9] ; Gloria,Barone ^[10] ; Samuel,Chan ^[3] ; Alexander,Hicks ^[3] ; Hannah,Bainbridge ^[3] ; David J,Pinato ^[11] ; Christian,Ottensmeier ^[12] ; Fabio,Gomes ^[13]

作者单位： Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy. Electronic address: giuseppe.banna@ircc.it. ^[1] Medical Oncology Department, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy. ^[2] Portsmouth Hospitals University NHS Trust, Portsmouth, UK. ^[3] University of Southampton, Southampton, UK. ^[4] Bristol Royal Infirmary, Bristol, UK. ^[5] Imperial College London, Hammersmith Hospital, London, UK. ^[6] University Hospital Geneva, Geneva, Switzerland. ^[7] University of Genoa, Genoa, Italy. ^[8] The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK. ^[9] United Lincolnshire Hospitals NHS Trust, Lincoln, UK. ^[10] Imperial College London, Hammersmith Hospital, London, UK; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy. ^[11] Clatterbridge Cancer Centre NHS Foundation Trust, University of Liverpool, Liverpool, UK. ^[12] The Christie NHS Foundation Trust, Manchester, UK. ^[13]

关键词 Chemoimmunotherapy Inflammatory index NLR prognostic Non-small-cell lung cancer Prognostic